• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·MCK
Held by 4 Gurus
Share

McKesson Corporation Stocks

$ 1060.84Last Updated 06.11.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 123.68B

$ 1060.84
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Stephen Mandel

Portfolio Weight (%)

0.3%

Change

-2.54%

Fund

Lone Pine Capital

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.2%

Change

-0.04%

Fund

Bridgewater Associates

Steven Cohen

Portfolio Weight (%)

0.1%

Change

+0.06%

Fund

Point72 Asset Management, L.P.

Manager
Fund
Portfolio Weight (%)
Change
Stephen MandelLone Pine Capital0.3%-2.54%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.2%-0.04%
Steven CohenPoint72 Asset Management, L.P.0.1%+0.06%
Show more

Latest news

22.09.2026 14:12

Morgan Stanley has updated its list of the top 15 stocks for the year. Last year's picks outperformed the S&P 500.

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of MCK is 1183 and suggests 11.5% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

08.11.2026 22:01

OpenAI Catches Up to Anthropic, Deals a Blow to Rival Nebius: Key Takeaways on the IPO Ahead of November 8

08.11.2026 15:01

Getting Stuck on the Same Thing: How News Concentration Affects Investors' Decisions

07.11.2026 23:21

'Air is coming out of the AI bubble': Strategists urge investors to buy after rout

07.11.2026 19:13

Berkshire has sharply accelerated its share buybacks. Should investors buy these shares?

07.11.2026 17:01

Small caps last week: Inovio approval, Alstom guidance cut, Once Upon a Farm recall

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026